Skip to main content
Lung cancer: expertise and cutting-edge treatments

Service(s) concerned

Structure(s) concerned

News

November pearl

Lung cancer: expertise and cutting-edge treatments

Therapeutic decisions are made during a weekly Multidisciplinary Tumor Board ( MTB ) of thoracic oncology involving onco-pulmonologists, pulmonologists , a radiotherapist , a radiologist, a nuclear medicine physician , a thoracic surgeon , an anatomical pathologist , a pain physician and a clinical research associate.

In 2022,

215 lung cancer surgeries were performed, 18 of which were carried out using an innovative, robot-assisted, minimally invasive surgical technique. This procedure is reserved for patients with early-stage lung cancer. It reduces pain, the risk of respiratory complications, and the length of hospital stay. It also promotes better recovery and healing.

Nearly 3,500 bags of chemotherapy and immunotherapy treatments were also prepared by the hospital's Cytotoxic Drug Preparation Unit and dispensed to patients. Each preparation is tailored to the patient's specific condition, weight, and overall health.

A wide range of support care is also available to patients (social, psychological, nutritional, sophrological and socio-aesthetic support and adapted physical activity ).

The pulmonology department is a reference center for the management of thymic tumors and mesothelioma.

Focus on the Pulmonary Intensive Care Unit

In this unit, six beds are dedicated to patients followed in the pulmonology and thoracic oncology department who have complications related to their illness and/or treatment. Here, they receive close 24/7 monitoring from a multidisciplinary medical team trained in critical care. Patients hospitalized in the ICU benefit from modern, automated, non-invasive equipment for optimal care. Monitoring systems continuously record the patient's vital signs and the operation of the various devices. Any anomaly is immediately signaled by an alarm.

Innovative therapies thanks to clinical research

The teams at Caen Normandy University Hospital are heavily involved in national and/or international clinical trials dedicated to lung cancer. Currently, around twenty lung cancer clinical trials are being conducted at the University Hospital, particularly at the hospital's Clinical Research Center.

The Clinical Research Center, accredited by the DGOS (Directorate General for Healthcare Provision), has site authorization issued by the Normandy Regional Health Agency to conduct phase 1 trials. Patients are cared for there by oncologists and pulmonologists from the Caen Normandy University Hospital, clinical research nurses, research engineers, and clinical research associates. Thanks to the clinical trials implemented, lung cancer patients have been able to benefit from innovative treatments within the institution (immunotherapy, targeted therapy) at various stages of their disease development.

Clinical research is an essential step in the development of new and innovative drugs and treatments. Clinical trials aim to evaluate new treatments and assess their efficacy and tolerability in patients. Indeed, a drug cannot be made available to patients without prior clinical trials.

Communication department of Caen Normandy University Hospital
CHU Caen Normandy

Press contacts

Department of Communication and Patronage
Avenue de la Côte de Nacre
CS 30001
14033 CAEN cedex 9